Additionally, clinical trials of an anti-PD-L1/TGF-βRII agent (SHR-1701) against NSCLC are ongoing (NCT03710265/NCT03774979), including EGFR-mutated NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.